Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 4, 2012

Evotec Inks €7.7M Compound Management Contract with EPA

  • The U.S. Environmental Protection Agency (EPA) awarded Evotec a multiyear, €7.7 million (approximately $10 million) compound management contract. The deal follows on from an initial contract with EPA in 2007. Under terms of the new agreement, Evotec’s San Francisco operation will provide chemical procurement, analysis, and sample preparation and management services to the EPA’s National Computational Center for Toxicology (NCCT). The services will support bioactivity profiling of EPA’s ToxCast™ (prioritization of Environmental Relevant Chemicals) compound library.

    “Providing key, efficient scientific infrastructures such as compound management is a key element of Evotec Execute,” comments Mario Polywka, Ph.D., Evotec COO. “This contract provides further long-term revenue and profitability for Evotec’s important compound management services business in San Francisco, which was acquired from BioFocus in 2011.”

    Evotec bought BioFocus’ San Francisco-based compound management business for €10.25 million up front and another potential €2.25 million in performance-related earn-out payments. 

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »